Seltorexant trial win points to busy market for new depression drugs

30 May 2024
johnson_big

Johnson & Johnson (NYSE: JNJ) has announced positive results from the Phase III MDD3001 trial for seltorexant, a selective orexin-2 receptor antagonist.

The study showed significant improvements in depressive symptoms and sleep disturbances in patients with major depressive disorder and insomnia.

The trial success comes as J&J signaled its belief that seltorexant could become one of around 15 new assets with blockbuster potential.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical